Latest news with #TempusOne
Yahoo
15-07-2025
- Business
- Yahoo
Tempus AI Raises 2025 Financial Outlook: What's Backing It?
Tempus AI TEM expects full-year 2025 revenues of $1.25 billion (up from the previous $1.24 billion guidance), which represents approximately 80% annual growth. The company also expects adjusted EBITDA of $5 million for the full year of 2025, an improvement of approximately $110 million over 2024. Robust First-Quarter Performance: Total sales in the first quarter amounted to $255.7 million, which grew 75.4% year over year. Quarterly gross profit increased 99.8% year over year, reaching $155.2 million. The gains were fueled by lab efficiencies, increased adoption of AI tools like Tempus One and xM and a higher mix of data services. These improvements narrowed down adjusted EBITDA loss to $16.2 million, from $43.9 million a year ago. Strategic Collaborations With AstraZeneca & Pathos: Tempus signed a three-year, $200 million data and modeling license agreement with AstraZeneca (AZN) and Pathos to build a multimodal foundation model in oncology, leveraging more than 300 petabytes of rich multimodal healthcare data that Tempus has built over the past decade. Notably, the deal raised the total remaining contract value to greater than $1 billion as of April-end. Upside in Hereditary Testing: Hereditary testing revenues hit $63.5 million on 23% volume growth, outpacing the first-quarter guidance. This growth was driven by the acquisition of Ambry Genetics, a recognized leader in genetic testing. The company anticipates long-term potential in this business beyond oncology, extending to cardiovascular, Alzheimer's and other genetic predispositions. For full-year 2025, Exact Sciences EXAS anticipates total revenues in the range of $3.070-$3.120 billion (previously $3.025-$3.085 billion). The adjusted EBITDA forecast is updated to the $425-$455 million band (up from the earlier range of $410-$440 million). A major catalyst for the guidance hike was the successful launch of Cologuard Plus, the company's next-generation colorectal cancer screening test. The test has already seen rapid adoption, with over 30,000 completed tests. TEM reported first-quarter revenues of $706.8 million, marking a 10.9% year-over-year increase. Adjusted EBITDA surged 61%, while free cash flow reached breakeven, an improvement of $120 million from the prior year. These results gave management the confidence to raise its full-year outlook. Exelixis EXEL raised its full-year 2025 financial guidance following strong first-quarter results, driven by higher demand for CABOMETYX and the recent U.S. FDA approval for its use in treating advanced neuroendocrine tumors (NET). The company expects total revenues in the range of $2.25-$2.35 billion (up from the earlier guidance range of $2.15-$2.25 billion). A major factor behind this upward revision was the FDA approval in March 2025 of CABOMETYX for the treatment of advanced pancreatic and extra-pancreatic NET, making it the first and only systemic treatment approved for previously treated NET regardless of tumor site or grade. Additionally, TEM is optimistic about several upcoming clinical milestones in the second half of the year, including pivotal trial readouts for its next-generation therapy zanzalintinib in colorectal and non-clear cell renal cancers. These developments reinforce Exelixis' strategy to expand its oncology portfolio and transition into a multi-franchise cancer company. In the past year, Tempus AI shares have surged 58.6%, outperforming the industry's 16.8% growth and the S&P 500 composite's 11% improvement. Image Source: Zacks Investment Research TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 7.09X compared to the industry average of 5.82X. Image Source: Zacks Investment Research Earnings estimates for Tempus AI in 2025 and 2026 are showing a mixed picture. Image Source: Zacks Investment Research TEM stock currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Exelixis, Inc. (EXEL) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report Tempus AI, Inc. (TEM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
04-07-2025
- Business
- Yahoo
Tempus AI Revenues & Profit Rise: What to Expect Ahead of Q2 Release
Tempus AI TEM is entering a phase of strong operating momentum, backed by significant acceleration in both revenues and gross profit. This trend became particularly clear in the company's last two reported quarters, which showed Tempus AI's transformation from a high-growth precision medicine startup to a scalable enterprise AI and diagnostics company with improving margins and profitability trends. In the fourth quarter of 2024, Tempus AI reported 35.8% year-over-year revenue growth, with gross profit rising 49.7%, driven by strong performance in its high-margin Data and Services segment. Momentum continued into the first quarter of 2025, as revenues grew 34% and gross profit climbed 45%, lifting gross margin from 42.5% to 44.5%. The gains were fueled by lab efficiencies, increased adoption of AI tools like Tempus One and xM and a higher mix of data services. These improvements also narrowed adjusted EBITDA losses by 61% sequentially. The company's upcoming second-quarter 2025 earnings release is expected to once again reflect margin expansion and sequential gains in adjusted EBITDA, driven by the adoption of new offerings such as Tempus One in EHR systems and the xM liquid biopsy assay. Any upward revision to guidance or increase in contract value, particularly from large enterprise deals, could strengthen the momentum seen in the first few months of the year. Given its strong margins and growing enterprise traction, Q2 performance could solidify Tempus AI's position as a rare AI-healthcare company combining high growth with improving financial discipline. Image Source: Zacks Investment Research Guardant Health GH: As a major player in blood-based cancer diagnostics, GH recently introduced Guardant Reveal, its latest minimal residual disease assay, now available for clinical research and under coverage review by major payors. Further, Guardant Health's Shield multi-cancer detection test recently received FDA Breakthrough Device designation, highlighting its strong clinical potential and regulatory momentum. In the first quarter of 2025, improved test sensitivity and cost efficiencies led to positive gross margins for both Reveal and Shield assays. Natera NTRA: It posted strong first-quarter 2025 results with 36.5% revenue growth and gross margin expansion to 63.1%. Positive cash flow and expanded Medicare coverage for its Signatera MRD assay, now including NSCLC and pan-cancer immunotherapy monitoring, position Natera to tap into a new multi-hundred-million-dollar market. Backed by robust ASCO data, Natera remains a high-growth peer in personalized oncology. The Zacks Consensus Estimate for Tempus AI's 2025 earnings implies a 56.3% improvement year over year. Image Source: Zacks Investment Research TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 7.52X compared with the industry average of 5.8X. Image Source: Zacks Investment Research Tempus AI currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Natera, Inc. (NTRA) : Free Stock Analysis Report Guardant Health, Inc. (GH) : Free Stock Analysis Report Tempus AI, Inc. (TEM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Business Insider
02-06-2025
- Business
- Business Insider
Tempus AI announces expansion of Tempus One
Tempus AI (TEM) announced the expansion of Tempus One-its generative AI clinical assistant-with direct integration into electronic health record, EHR, systems. By integrating AI at every point of the clinical care process, the expanded capabilities of Tempus One offer physicians in oncology and beyond more support in treatment decisions. Tempus One is uniquely positioned to offer these new features given the company's depth and scale of EHR integrations with providers across the U.S. Confident Investing Starts Here:
Business Wire
01-06-2025
- Business
- Business Wire
Introducing Tempus One in the EHR with Integrated Guidelines
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of Tempus One—its generative AI clinical assistant—with direct integration into electronic health record (EHR) systems. By integrating AI at every point of the clinical care process, the expanded capabilities of Tempus One offer physicians in oncology and beyond more support in treatment decisions. Tempus One is uniquely positioned to offer these new features given the company's depth and scale of EHR integrations with providers across the U.S. Tempus has developed an integrated architecture that captures real-time clinical, molecular and imaging data from millions of patients and makes that data easily digestible and useful for clinicians and care teams. Through Tempus One, physicians can gain AI-enabled insights that transform how they interact with patient data, streamlining complex treatment decisions and reducing time spent on administrative tasks. New capabilities in the latest iteration of Tempus One: Integration of ASCO Guidelines: Tempus One is integrating ASCO's clinical practice guidelines into the platform to equip physicians with the latest guidelines and information to guide personalized patient care. Oncologists are now able to easily access ASCO's guidelines, which provide evidence-based, treatment and care recommendations. Clinical Workflow Assistance: Tempus One has a suite of new features, designed to help physicians at every step with tailored insights and reduce the burden of administrative tasks. Pre-Appointment Preparation: Tempus One summarizes patient history, treatment journey, and recent biomarker status, ensuring physicians are well-prepared for appointments. Real-Time Support During Appointments: Tempus One can transcribe conversations, take intelligent notes, and highlight key information, allowing physicians to focus on patient care. Post-Appointment Assistance: Tempus One supports documentation tasks, treatment planning based on updated guidelines and research, prepares prior authorizations, and facilitates clinical trial matching. Agent Builder: Over the past several months, Tempus has used its Agent Builder GenAI tool internally to develop and deploy more than 1,000 AI agents. Now, Tempus is extending access to this toolset to a select group of partner providers, collaborating with them to create and test custom GenAI solutions tailored to their unique needs and preferences. The agents are designed to create efficiencies and streamline workflows, such as generating custom patient overviews to accelerate pre-charting or generating notes from conversations with patients to be added into their EHR records. These custom agents can be developed in collaboration with dedicated Tempus team members. By referencing institutions' standard operating procedures and data repositories, these agents can be seamlessly integrated into existing workflows through One. 'As healthcare faces rising costs and growing complexity, no group bears the burden more heavily than physicians and care teams,' said Ryan Fukushima, Chief Operating Officer at Tempus. 'This evolution of Tempus One represents a meaningful shift from a world where clinicians spend countless hours searching for answers and documenting care, to one where AI rapidly connects the dots across fragmented systems to deliver actionable insights in real time.' To learn more about Tempus One, view a video here and visit the website here. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the expected outcomes and benefits of Tempus One and its capabilities for customers. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'going to,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled 'Risk Factors' in Tempus' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
Yahoo
01-03-2025
- Business
- Yahoo
SCOPE 2025: investors share optimism and obstacles for AI in clinical operations
Clinical operations teams can expect a tremendous return on investments in artificial intelligence (AI) in the next 5–10 years, according to speakers from pharmaceutical and biotech companies and investors speaking at SCOPE 2025 in Orlando, Florida, on 4-5 February 2025. Experts participating in the conference's Clinical Trial Innovation, Venture, and Partnering stream shared that they are increasingly using AI to streamline, support, and enhance their clinical operations. According to GlobalData forecasts, the pharmaceutical industry is expected to spend over $407m on AI platforms by 2028, up from $46.9m in 2019, representing a compound annual growth rate (CAGR) of 24.1% (Figure 1). Companies will spend more on AI consulting and support services than on AI platforms and AI hardware, with estimates at over $2bn by 2028, up from $178.9m in 2019, representing a CAGR of 27.5%. However, investors cautioned that all stakeholders within a company must first adopt AI, and that AI must pass through regulatory checkpoints. The investor panel at SCOPE highlighted Tempus AI (Chicago, Illinois), as a success story in the pharmaceutical space for the adoption of AI. Tempus is a healthcare technology company that uses AI to collect and analyse molecular, clinical, and genomic data. At the beginning of the year, it introduced new generative AI capabilities for its AI assistant, Tempus One, which now uses the company's proprietary large-language learning model (LLM) to advance data-driven support in clinical care and research. According to GlobalData's Company Filing Analytics, Tempus AI shared that it 'plan[s] to continue to invest in technology personnel to support [its] Platform and new algorithm development'. GlobalData's Job Analytics reports a 74% increase in AI hiring trends in the past month for the company. Although investors stated that the industry is coming out of a 'biotech funding winter,' they noted that there is still a need to find new ways to decrease drug development costs, and that technologies such as LLMs can bring down the cost of development. According to GlobalData's Deals database, pharmaceutical venture financing deals related to AI have increased 44% from 2023 to 2024, and 55% from 2022 to 2024 (Figure 2). Aside from the push for innovation to decrease costs, large pharmaceutical companies are recognising that there is also a need to increase efficiency in clinical trials, with this need exacerbated by a significant drug patent cliff in 2026–27, according to investors at SCOPE. GlobalData's Catalyst Calendar reports that 1,210 constraining patent expiries are expected for the US, EU, and Japan in 2026 and 2027. By 2034, 1,142 constraining patents will expire in the US, EU, and Japan (Figure 3). The number is expected to increase over the next decade, highlighting the capacity problem in drug development. AI is the solution to this throughput problem, according to key opinion leaders at SCOPE. To address this capacity problem in drug development, speakers at SCOPE also suggested creating more capacity through better patient recruitment and clinical operations—where site enablement and clinical data innovation were noted as areas of investment for venture capitalists. Advancements in AI and other technologies can speed up long patient recruitment timelines and resolve issues, such as missing a demographic of patients in certain zip codes due to limited access or losing patients through poor engagement. AI-enabled technologies need to be scalable solutions that can be widely used by the pharmaceutical industry. The adoption of technologies that are too siloed may be difficult if one works with multiple vendors. Zachary Taft, CEO of IgniteData (Wilmington, Delaware), shared that there is a 'disconnect between CROs and pharmaceutical [companies], where the technology needs to be implemented into preexisting systems in a way that is vendor-agnostic.' Investors and other key opinion leaders also noted that AI-enabled solutions need to be able to integrate seamlessly into a company's current infrastructure or day-to-day. 'We're not just building platforms anymore. We're building an ecosystem,' stated Brian Martin, a senior research fellow at AbbVie (Chicago, Illinois). "SCOPE 2025: investors share optimism and obstacles for AI in clinical operations" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
